Complications Following Percutaneous Mitral Valve Repair

• Published in: Frontiers in cardiovascular medicine Vol. 6; p. 146
• Main Authors: Gheorghe, Livia, Ielasi, Alfonso, Rensing, Benno J. W. M., Eefting, Frank D., Timmers, Leo, Latib, Azeem, Swaans, Martin J.
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 18.10.2019
• Subjects: Cardiovascular Medicine; Carillon device; complications; MitraClip; mitral valve (MV) repair; Mitralign; transcatheter interventions
• ISSN: 2297-055X; 2297-055X
• DOI: 10.3389/fcvm.2019.00146

Mitral valve disease affects more than 4 million people in the United States and it is the second most prevalent valvulopathy in Europe. The gold standard of treatment in these patients is surgical repair or mitral valve replacement. In the last decade, numerous transcatheter therapies have been developed to overcome the increased number of subjects with symptomatic severe mitral regurgitation and high surgical risk. The Mitraclip (Abbott Vascular, Menlo Park, CA), PASCAL (Edwards Lifesciences, Irvine, CA, USA), the Carillon™ Mitral Contour System™ (Cardiac Dimension Inc., Kirkland, WA, USA), the Mitralign™ (Mitralign, Tewksbury, Massachusetts), and the Cardioband (Edwards Lifesciences, Irvine, CA) are the principal percutaneous devices for mitral valve repair. We present an evidence-based clinical update that provides an overview of these technologies and their potential complications.